Develops products using vaccine-like technology for neutralizing hormones which participate in gastrointestinal system and reproductive system cancer and non-cancer diseases and the prevention of pregnancy. Based in Miami, Florida. (Nasdaq: APHT)

Targeting multiple sclerosis, chronic autoimmune and allergic disorders, using patented technology for design of peptide apitopes. Includes bibliography and contacts in Bristol, England.

Company developing therapeutics of aptamers, for the prevention and treatment of chronic and acute disease. Includes overview of technology and commercial potential, careers and contacts in Cambridge, Massachusetts.

Receptor-based drug discovery in the fields of diabetes, obesity, cardiovascular, sleep disorders, neurodegeneration, schizophrenia, depression and anxiety. Comprehensive profile of company in San Diego, California. (Nasdaq: ARNA)

Developing diagnostics and drugs from core discoveries in protein and polysaccharide chemistry, including anti-viral attachment inhibitors. Includes research overview, distributors, and offices in Chicago and Santa Monica, California.

Develops and commercializes a vaccine against human chorionic gonadotropin secreting cancers, and synthetic antisense technology to inhibit translation in treating cardiovascular, kidney and viral diseases. Research and manufacturing facilities in Corvallis, Oregon. (Nasdaq: AVII)

Develops gene-based therapeutic products derived from adeno-associated virus for the treatment of inherited and acquired diseases. Includes explanation of technology, product pipeline, collaborative partnerships and investment data, from manufacturing facility in Alameda, California. (Nasdaq: AVGN)

Company founded in 1997 to develop new therapies for bone diseases. Outlines products under development and news from Montreal, Canada.

Innovating viral phospholipase inhibitor to prevent expression of Herpes specific genes, and intracellular viral antigens, and drug inducing death of tumor cells and autoreactive immune cells, in multiple sclerosis, rheumatism, and Crohn's disease. Based in Leverkusen, Germany.

Company focusing on G-protein coupled receptor signaling as targets for therapeutic products. Includes corporate data, partnering and technology overviews, with media resources, list of publications, and opportunities in Chicago, Illinois.

Developing small molecule and peptide drugs in regulatory signaling and regenerative pathways. Introduces technical background, product pipeline, collaborations, investment data and careers headquartered from Cambridge, Massachusetts. (Nasdaq: CVGP)

Identifies and characterises structural variants of polyketides and non-ribosomal cyclic heptapeptides from cyanobacteria, and optimises pharmacological activity using biocombinatorial techniques. Profile, collaborators and contacts in Germany.

Engaged in the identification, validation and selection of novel drugable targets and product candidates for the diagnosis and treatment of chronic inflammatory diseases. Profiles of technology, product pipeline and corporation in Labege, France.

Researches and develops biopharmaceutical products which address the role of blood and blood vessels in the prevention and treatment of diseases by inhibiting growth or enhancing bioavailability of drugs. Based in Rockville, Maryland. (Nasdaq: ENMD)

Researching diagnostics and drug candidates for the treatment of amyotrophic lateral and multiple sclerosis, as well as autoimmune diseases, including anti-idiotypic antibodies. Includes overview of corporation in Cenon, France.

Discovers, develops and commercializes therapies for systemic lupus erythematosus, viral diseases and cancer. Located in Redwood City, California.(Nasdaq: GNLB)

Genetic engineering techniques in the discovery, development, production, and marketing of human therapeutics. Includes research history, product pipline, global corporate and career information, from South San Francisco, California.

Researching nuclear receptors and gene deregulation for treatment of cardiovascular, metabolic and inflammatory diseases. Includes information about genomic research headquartered in Loos, France.

Developer of blood substitute, aiming to address intrinsic hemoglobin toxicity. Introduction to company and their work, with form to contact Dallas, Texas.

Engaged in the discovery and development of novel therapeutics and diagnostics using synthetic DNA and antisense technology. Based in Cambridge, Massachusetts. (AMEX: HBY)

Researches and develops growth factor blockers and anti-cancer vaccines. Includes clinical programs, investor details and overview of company in New York City. (Nasdaq: IMCL)

Developing novel drugs against targets inside nerve cells to treat CNS disorders. Includes therapeutic projects, target biochemistry, corporate data and contacts for headquarters in New York City.

Develops antibacterial and antifungal drugs, including protegrins and related antimicrobial peptides, for application in cystic fibrosis. Includes pipeline, publications, and investor information from Palo Alto, California. (Nasdaq: IBPI)

Developing a pulmonary insulin delivery system, and immunotherapy of cancer, by identifying tumor-related antigens, DNA and peptide-based drugs evoking cell-mediated responses. Located in Valencia, California.

Develops proprietary protein modifications including PEG, glycosylation and vaccines. Overview of technologies, clinical trial pipeline, investor data and careers in Redwood City, California. (Nasdaq: MAXY)

A privately held company that specializes in research for treatment of cancer, diabetes, multiple sclerosis, HIV/AIDS and infectious diseases, including Lyme Disease. Lists research projects and procedures. Based in San Diego, California.

Specialist in the design, development, and marketing of human cell replacement therapy systems, targeting inflammatory disease. Includes directions to research labs at Ann Arbor, Michigan, and corporate offices in Lincoln, Rhode Island.

Drug discovery and development company using pathway engineering and chemistry to optimise the activity of natural products for the treatment of infectious diseases. Introduces biotransformation technology, lead compounds, key personnel in Hatfield, England.

Researches and develops neurological diagnostics and pharmaceuticals for the aging population with emphasis on Alzheimer's disease. Profile of company with bases in Maywood, New Jersey and Saint Laurent, Quebec. (Nasdaq: NYMX)

Develops peptide-based therapeutics for the treatment of human hormone diseases, prostate cancer endometriosis, and inflammatory diseases. Includes therapeutic targets and profile of facilities in Waltham, Massachusetts. (Nasdaq: PRCS)

Structure-based drug design start-up, specializing in the ribosome as a target, and bacterial antibiotic resistance. Includes mechanisms of action, glossary, careers, corporate news and contacts and directions in New Haven, Connecticut.

Developing drugs and therapies to reverse the effects of human aging by focusing on preserving the length of telomeres, to keep them more resilient. Careers in Reno, Nevada.

Applies human receptor-targeted drug design technology to discover and clone genes and to design G protein-coupled receptor agonist and antagonists. Based in Paramus, New Jersey. (Nasdaq: SNAP)

Development of superactive hormones and growth factors for therapeutic applications. Based in Rockville, Maryland, USA.

Specializes in age-related diseases. Includes patient links for Alzheimer's Disease, clinical trials, company news and careers in Raleigh, North Carolina.

Technology for MHC epitope removal, glycosylation to optimize pharmacokinetics, masking immune recognition sites and engineering monoclonal antibodies. Includes discovery programs, partnering opportunities in Monrovia, California. ImmunoPDA? Technology Product Sheet Caltech spin-off developing proteomic technologies to accelerate drug discovery.

Holding company for drug discovery subsidiaries, developing anti-cancer compounds in clinical stage, and addiction vaccines. Includes candidates for therapeutic focus, investor details, with contacts in Slough and Cambridge, England. (Nasdaq: XNVA)

Development and manufacture of recombinant proteins and peptides, in partnership with big pharmas. Includes licensing of technology derived from the host-defense protein BPI, monoclonal antibodies to treat chemotherapy-induced thrombocytopenia, and to target cancer. Based in Berkeley, California.

Discovery, development and commercialization of therapeutic proteins for the prevention and treatment of human diseases. Includes product pipeline, news on clinical trials and profile of company in Seattle, Washington.